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Rather, a more likely pathway—and one
that should be tested in future studies—
is one wherein ethanol metabolism by he-
patocytes generates paracrine signals
that drive 2-AG synthesis by stellate cells.
Paracrine stimulation of CB1 receptor
signaling in hepatocytes by 2-AG derived
from neighboring stellate cells is a major
finding of the Jeong et al. study. The
importance of hepatocyte responses to
2-AG was confirmed first by using rimo-
nabant to attenuate CB1 signaling and
thereby block steatosis in vivo, and then
by assessing the effects of ethanol in
mice selectively deficient in CB1 recep-
tors only in hepatocytes. These liver-
specific CB1 receptor knockout mice are
particularly useful in that they avoid any
confounding effects of CB1 signaling in
the central nervous system, where the re-
ceptor is far more abundantly expressed
than in liver. Animals with hepatocyte-
specific deletion of CB1 receptors were
resistant to the steatotic effects of ethanol
feeding. Moreover, induction of the lipo-
genic mediators sterol regulatory ele-
ment-binding protein 1c (SREBP-1c) and
fatty acid synthase (FAS) was blunted
and activity of carnitine palmitoyltransfer-
ase 1 (CPT1) was no longer inhibited in
mice with either global or hepatocyte-
specific deletion of CB1 receptors. It
would be informative to determine
whether CYP2E1 expression is addition-
ally affected by CB1 loss, as this could at-
tenuate liver injury by reducing oxidative
stress.
The intriguing findings of Jeong et al.
(2008) introduce a new paradigm in our
understanding of fatty liver and its poten-
tial attenuation by available pharmacolog-
ical agents. Paracrine signaling by a non-
parenchymal cell to modulate hepatocyte
responses may be relevant to a number of
intermediary pathways apart from fat me-
tabolism, including homeostasis of carbo-
hydrates, proteins, vitamins, and metals
(especially iron and copper). Effects of
Kupffer cells and sinusoidal endothelial
cells as other sources of paracrine stimuli
should also be considered in order to dis-
sect whether these effects derive exclu-
sively from stellate cells, although this
seems unlikely. It is possible, but still
unproven, that the paracrine pathway de-
scribed by Jeong et al. (2008) could con-
tribute to fatty liver due to etiologies other
than alcohol, especially NAFLD.
In summary, the uncovering of para-
crine cannabinoid signaling as a determi-
nant of hepatic steatosis unveils exciting
new possibilities for both understanding
and regulating fat accumulation in liver.
Combined with data implicating cannabi-
noids in hepatic fibrogenesis, this path-
way is assuming a central role in the reg-
ulation of hepatic metabolism, injury,
and fibrosis.
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Bone homeostasis is a well-balanced process that is largely dependent on the contribution of both bone-
forming osteoblasts and bone-resorbing osteoclasts. A new study (Wan et al., 2007) suggests a previously
unsuspected role for the transcription factor PPARg in promoting bone progenitors to the osteoclastic
lineage.The Italian anatomist Niccolo` Massa un-
doubtedly appreciated the paramount im-
portance of bones when he wrote as early
as 1559 that ‘‘if any one is ignorant of the188 Cell Metabolism 7, March 2008 ª2008 Estructure of the bones it follows necessar-
ily that he will be ignorant of very many
other things along with them.’’ Several
centuries later, bone is still a prime subjectlsevier Inc.of modern biomedical research for many
reasons, including that bone diseases,
such as osteoporosis, osteopetrosis,
arthritis, osteosarcoma, and others, are
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PreviewsFigure 1. Effects of PPARg on Bone Cell Differentiation
Deletion of PPARg in mouse osteoclast precursors causes osteopetrosis due to impaired osteoclast differentiation from hematopoietic stem cells (HSCs). PPARg
ligand activation by rosiglitazone promotes osteoclast differentiation. In osteoclast precursor cells, activated PPARg forms a heterodimer with retinoid X receptor
a (RXRa) and enhances c-fos expression, which then stimulates osteoclastogenesis (Wan et al., 2007). Conversely, PPARg downregulates osteogenesis by driv-
ing competition between adipogenic and osteoblastic differentiation of bone marrow progenitors (MSCs) in favor of adipogenesis (Akune et al., 2004; Cock et al.,
2004). Osteoblasts are supporting cells for osteoclast differentiation that express the membrane-bound osteoclastogenic cytokine receptor activator of NF-kB
ligand (RANKL) andmacrophage colony-stimulating factor (M-CSF). Osteoclast precursors express receptors for RANKL (RANK) and for M-CSF (M-CSFR, mac-
rophage colony-stimulating factor receptor), through which osteoblasts signal to osteoclast precursors to impact on their fate.serious and painful diseases that can im-
pair the mobility of patients and thus their
independence.
Osteoblasts and osteoclasts are es-
sential in controlling the amount of bone
tissue. Healthy bones undergo dynamic
remodeling throughout life, being re-
shaped by the osteoblasts, which are
responsible for bone formation, and the
osteoclasts, which resorb bone by remov-
ing both its organic and inorganic compo-
nents. A new role for the peroxisome pro-
liferator-activated receptor g (PPARg) in
the maintenance of bone homeostasis
has emerged, as illustrated by the recent
work of Evans and colleagues on osteo-
clastogenesis (Wan et al., 2007). Previ-
ously recognized key roles of this ligand-
activated nuclear receptor were mainly
in glucose and fat metabolism and in in-
flammation. The antidiabetic thiazolidine-
diones (TZDs) rosiglitazone and pioglita-zone are agonists of PPARg. These
drugs are extremely well tolerated and
have become popular in the treatment of
type 2 diabetes. However, they have
been much debated because a rare side
effect of TZD treatment, fluid retention,
can worsen congestive heart failure. Con-
sequently, TZDs are not recommended
for treatment of diabetic patients with
moderate or severe heart failure.
Furthermore, in several clinical trials, in-
cluding A Diabetes Outcome Progression
Trial (ADOPT), which involved 4360 type 2
diabetes patients, an unexpected higher
rate of fractures has been observed in
groups that received rosiglitazone or pio-
glitazone treatment (Grey, 2008; Kahn
et al., 2006). In animal studies, TZD treat-
ments have demonstrated decreased
bone formation and bone mass (Grey,
2008). These outcomes, which suggest
that bone is vulnerable to antidiabeticCell Metabotherapies with PPARg agonists, raised
an important clinical issue regarding the
potential role of PPARg in bone loss.
In their recent study, Wan et al. (2007)
report a previously unrecognized role of
PPARg in promoting osteoclast differenti-
ation and bone resorption when activated
by rosiglitazone (Figure 1). In this work,
mice with a deletion of PPARg in osteo-
clasts, but not in osteoblasts, developed
a phenotype of increased bone mass
and density and extramedullary hemato-
poiesis. This phenotype corresponds to
the clinical syndrome called osteopetro-
sis, first described by the German radiolo-
gist Heinrich Albers-Scho¨nberg in 1904,
which is characterized by impaired bone
resorption, resulting in skeletal fragility de-
spite increased bone mass. Wan, Chong,
and Evans (Wan et al., 2007) also used
the converse approach, which consisted
of a gain of PPARg function by activatinglism 7, March 2008 ª2008 Elsevier Inc. 189
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Previewsthe receptor with rosiglitazone. This treat-
ment accelerated osteoclast differentia-
tion and bone resorption in a PPARg-
dependent manner. In a series of elegant
experiments, the molecular pathway by
which PPARg exerts its osteoclastogenic
effect was revealed. PPARg and its li-
gands promote osteoclast differentiation
by controlling the c-fos gene,whoseprod-
uct was identified previously as a key reg-
ulator of the macrophage/osteoclast line-
age and bone remodeling (Grigoriadis
et al., 1994). The results of Wan et al.
(2007) show that PPARg deficiency selec-
tively inhibits the c-fos arm of the mem-
brane-bound receptor activator of NF-kB
ligand (RANKL) signaling pathways.
An intriguing observation reported
a few years ago was that osteoclasts
cannot be derived from marrow macro-
phages unless they are cocultured with
osteoblasts or their stromal cell precur-
sors (Novack and Teitelbaum, 2008).
Osteoblasts express RANKL and macro-
phage colony-stimulating factor (M-CSF),
key osteoclastogenic cytokines (Figure 1).
The crucial role of osteoblasts in osteo-
clastogenesis, via these cytokines, raises
the question of whether PPARg inhibits
osteoblast differentiation directly or indi-
rectly, which would thus confer on this nu-
clear receptor an overall control function
determining the fate of the two major
bone cell populations.
Osteoblasts and adipocytes are both
generated from multipotent mesenchy-
mal stem cells (MSCs) in bone marrow,
and PPARg is now recognized as a key
adipogenic factor (Figure 1). Interestingly,
age-related osteoporosis is concomitant
with increased marrow adipose tissue. In
a cell culture assay, PPARg-deficient em-
bryonic stem cells spontaneously differ-
entiated into osteoblasts and failed to
produce adipocytes, indicating that the
receptor favors adipogenesis over osteo-
blastogenesis (Akune et al., 2004) (Fig-
ure 1). In mice, PPARg insufficiency
increases bone mass due to enhanced
osteoblastogenesis from bone marrow
progenitors, suggesting that the receptor
functions as a suppressor of commitment
to the osteoblastic lineage (Akune et al.,190 Cell Metabolism 7, March 2008 ª2008 E2004; Cock et al., 2004). Thus, PPARg
acts on bone metabolism by stimulating
and inhibiting the osteoclastogenic and
osteoblastogenic pathways, respectively
(Figure 1). Importantly, Wan et al. (2007)
genetically separated the effect of PPARg
on the hematopoietic lineage, which pro-
duces osteoclasts, from its effect on the
mesenchymal lineage, which gives rise
to osteoblasts. This was achieved by
crossing Tie2Cre mice with homozygous
PPARg floxedmice, causing PPARg abla-
tion only in the hematopoietic lineage,
which includes endothelial cells, bone
marrow, thymus, spleen, and lymph nodes,
without affecting the mesenchymal
lineage. This enabled the investigators to
analyze PPARg function in only one of
the two cell populations, the osteoclasts.
However, this approach does not allow
definitive dismissal of the possibility, al-
though unlikely, that PPARg deletion in
other hematopoietic cells also affects
the osteoclast progenitor cell population.
This question will be answered when
targeted deletion exclusively in osteo-
clasts becomes possible. Furthermore,
Wan et al. used synthetic PPARg ligands,
and it remains to be investigated which,
how, and when natural biological PPARg
ligands interfere with the large degree of
plasticity of osteoclast as well as osteo-
blast progenitor cells.
Taken together, these recent findings
on the roles of PPARg should inspire
new approaches to preventing metabolic
deregulation in bones and treating bone
diseases associated with increased
bone loss. The potential for the pharma-
cological targeting of progenitor cells to
increase bone regeneration is also rein-
forced by the finding that the differentia-
tion of preosteoblasts to osteoblasts can
be increased by the proteasome inhibitor
bortezomib. This effect was observed in
multiple myeloma patients suffering from
bone lesions due to osteoclast-activating
factors released by the tumor cells, which
stimulate osteoclasts to break down
bone (Giuliani et al., 2007). In mice, this
antimyeloma proteasome inhibitor in-
duces mesenchymal stem/progenitor
cells, which can differentiate into bone,lsevier Inc.fat, or muscle, to preferentially undergo
osteoblastic differentiation (Mukherjee
et al., 2008).
In conclusion, the recent advances in
osteoclast and osteoblast biology open
opportunities for the exploration of com-
bination therapies with agents that pro-
mote regenerative functions and bone
maintenance by stimulating osteoblast
differentiation and/or by inhibiting osteo-
clastic bone destruction. Furthermore, if
such agents have antineoplastic activity,
they may be beneficial for multiple mye-
loma patients with severe bone disease.
New knowledge such as that gained
through the study of Wan et al. (2007),
when combined with PPARg cell-type-
selectivemodulators still to be developed,
will win over PPARg as an ally rather than
a foe by promoting solely its beneficial
effects on altered bone metabolism.
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